CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Phase 1 Recruiting
42 enrolled
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Phase 3 Recruiting
360 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2 Recruiting
160 enrolled
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/2 Recruiting
316 enrolled
MOUNTAINEER-03
Phase 3 Recruiting
400 enrolled
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Phase 3 Recruiting
726 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Phase 2 Recruiting
30 enrolled
EmpowHER 208
Phase 2 Recruiting
125 enrolled
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Phase 1 Recruiting
20 enrolled
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Phase 3 Recruiting
840 enrolled
CAPTUR
Phase 2 Recruiting
720 enrolled
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Phase 2 Recruiting
37 enrolled
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Phase 2 Recruiting
53 enrolled
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Phase 3 Recruiting
550 enrolled
A Study of Surgery and Radiotherapy in People With Breast Cancer
Phase 2 Recruiting
162 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
Phase 4 Recruiting
10 enrolled
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Phase 2 Recruiting
30 enrolled
H3RAKLES
Phase 2 Recruiting
20 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
MK-1022-009
Phase 1/2 Recruiting
81 enrolled
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Phase 2 Recruiting
36 enrolled
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Phase 2 Recruiting
50 enrolled
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Phase 3 Recruiting
1,524 enrolled
ASPEN-09
Phase 1/2 Recruiting
80 enrolled
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 3 Recruiting
740 enrolled
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 Recruiting
49 enrolled
ROSETTE
Phase 2 Recruiting
84 enrolled
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3 Recruiting
555 enrolled
TAYLOR
Phase 2 Recruiting
200 enrolled
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Phase 2 Recruiting
146 enrolled
RAGE
Phase 1/2 Recruiting
48 enrolled
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Phase 3 Recruiting
400 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
TRIFLUOX-DP
Phase 2 Recruiting
73 enrolled
DETERMINE
Phase 2/3 Recruiting
825 enrolled
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Phase 2 Recruiting
25 enrolled
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Phase 3 Recruiting
300 enrolled
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3 Recruiting
544 enrolled
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2 Recruiting
39 enrolled
PIKture-01
Phase 1 Recruiting
200 enrolled
ARIADNE
Phase 2 Recruiting
370 enrolled
The Sagittarius Trial
Phase 3 Recruiting
700 enrolled
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Phase 2 Recruiting
200 enrolled
TRAP-BTC
Phase 2 Recruiting
24 enrolled
ProTarget
Phase 2 Recruiting
300 enrolled